CVChristiane Viedt

Christiane Viedt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christiane Viedt has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The nucleotide analogue 3-deazaadenosine prevents neointima-formation after balloon injury

    by Florian H. Seeger, Wolfram Hess, Daniel Sedding, Gunter Becker, Ralf Kinscherf, Ruediger C. Braun-Dullaeus, Christiane Viedt, Jörg Kreuzer

  • Role of p22phox in angiotensin II and platelet-derived growth factor AA induced activator protein 1 activation in vascular smooth muscle cells

    by Christiane Viedt, Jianwei Fei, Heidemarie I. Krieger-Brauer, Ralf P. Brandes, Daniel Teupser, Motohiro Kamimura, Hugo A. Katus, Jörg Kreuzer

    Reactive oxygen species (ROS) are involved in the transcriptional response to angiotensin (ANG) II. In this setting the role of NAD(P)H oxidase, an important source of ROS as second messengers, is not completely understood. In particular in human cells detailed insights into this mechanism are lacking. We investigated the role of ANG II and platelet-derived growth factor (PDGF) AA induced ROS generation derived from p22phox-containing NAD(P)H oxidase in the activation of activator protein (AP) 1 in human vascular smooth muscle cells (SMCs). Both ANG II and PDGF AA induced ROS generation in SMCs which was angiotensin type 1 receptor and PDGF α receptor dependent. Specific inhibition of the p22phox subunit of the NAD(P)H oxidase using either p22phox neutralizing antibody or p22phox antisense oligodeoxynucleotides (ODNs) attenuated both ANG II and PDGF AA induced ROS generation. Furthermore, PDGF AA but not ANG II induced p22phox mRNA expression. ANG II and PDGF AA both activated the redox-sensitive transcription factor AP-1, which was inhibited by p22phox antisense ODNs. These findings demonstrate that AP-1 activation in human SMCs in response to ANG II and PDGF AA is mediated via generation of p22phox-dependent ROS. This highlights the crucial role of the p22phox-containing NAD(P)H oxidase in the ANG II and PDGF AA induced signal transduction pathway.


  • HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9

    by Christiane Viedt, Weili Shen, Jianwei Fei, Motohiro Kamimura, Gertrud M. Hänsch, Hugo A. Katus, Jörg Kreuzer

    The terminal complement complex C5b-9 is known to participate in inflammatory processes including atherosclerosis. Inflammation appears to be a direct consequence of C5b-9-mediated cell stimulation. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors may exert anti-inflammatory effects on vascular cells independent of lowering plasma cholesterol. Thus, we studied activation of vascular smooth muscle cells (VSMCs) by C5b-9 focusing on whether inhibition of the HMG-CoA reductase can reduce the proinflammatory effects of C5b-9. C5b-9 in sublytic concentrations increased the proliferation of human VSMCs and induced a time-dependent activation of the mitogen-activated protein (MAP) kinase extracellular signal-regulated kinase (ERK). Proliferation and ERK1/2 activation could be inhibited by the specific ERK inhibitor PD98059. HMG-CoA inhibition with cerivastatin-reduced VSMC proliferation and C5b-9-induced ERK1/2 activation. Cerivastatin also reduced the C5b-9-induced synthesis of the proinflammatory interleukin-6 (IL-6). Furthermore, C5b-9 induced activation of the transcription factors activator protein- 1 (AP-1) and nuclear factor-kappaB (NF-κB), which could be inhibited by pretreatment of VSMCs with cerivastatin. L-mevalonate and geranylgeranylpyrophosphate reversed the inhibitory effects of cerivastatin. The present study in VSMCs shows that cerivastatin inhibits IL-6 synthesis and cell proliferation induced by the terminal complement complex C5b-9. This may be an important mechanism contributing to the beneficial effects of HMG-CoA reductase inhibitors beyond lowering of plasma cholesterol.